CTLA4 and hepatocellular carcinoma: A phase I/II trial assessed the combination of anti-PD-L1 antibody (durvalumab) and anti-CTLA-4 antibody (tremelimumab) in 40 patients with advanced HCC and demonstrated a response rate of 25%; highlighting the benefit of combined approach over monotherapy with tolerable toxicity profile.